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Medication prescribing and dispensing often regarded as one of the most effective ways to manage and
improve population health. Prescribed and dispensed medications can be monitored through data linkage
for each patient. We hypothesised that changes in patient care resulting from COVID-19, changed the way
patients access their prescribed medication.
Objective To develop an e cient approach for evaluation of the impact of COVID-19 on drug dispensing
patterns.
Methods
Retrospective observational study using national patient-level dispensing records in Wales-UK. Total
dispensed drug items between 01-Jan-2016 and 31-Dec-2019 (counterfactual pre-COVID-19) were
compared to 2020 (COVID-19 year). We compared trends of dispensed items in three main British
National Formulary (BNF) sections(Cardiovascular system, Central Nervous System, Immunological &
Vaccine) using European Age-Standardized rates. We developed an online tool to enable monitoring of
changes in dispensing as the pandemic evolves.
Result
Amongst all BNF chapters, 52,357,639 items were dispensed in 2020 compared to 49,747,141 items in
2019 demonstrating a relative increase of 5.25% in 2020(95%CI[5.21,5.29]). Comparison of monthly
patterns of 2020 and 2019 dispensed items showed a notable difference between the total number of
dispensed drug items each month, with an average difference (D) of +290,055 and average Relative
Change (RC) of +5.52%. The greatest RC was observed in a substantial March-2020 increase
(D=+1,501,242 and RC=+28%), followed by second peak in June (D=+565,004, RC=+10.97%). May was
characterised by lower dispensing (D=-399,244, RC=-5.9%). Cardiovascular categories were characterised,
across all age groups, by dramatic March-2020 increases, at the epidemic peak, followed by months of
lower than expected dispensing, and gradual recovery by September. The Central Nervous System
category was similar, but with only a short decline in May, and quicker recovery. A stand-out grouping was
Immunological and Vaccine, which dropped to very low levels across all age groups, and all months
(including the March dispensing peak).
Conclusions
Aberration in clinical service delivery during COVID-19 led to substantial changes in community pharmacy
drug dispensing. This change may contribute to a long-term burden of COVID-19, raising the importance




The novel coronavirus disease 2019 (COVID-19) pandemic has resulted in unprecedented changes on
health care services provision (1). While technology has provided an increase in telephone or virtual
appointments there has been an overall net reduction in primary care appointments (2). Increase in
demand for essential medicines coupled with complex medicines supply chain issues, enforcement of
social distancing, quarantine, and self-isolation has impacted the prescribing and dispensing of
medicines (3)(4).
Studies using survey and patient data, reported an observed change in medication use during the
pandemic (5)(6). Changes in service delivery have been monitored through multiple national audits which
often lag considerably behind in real-time (7)(8). There is an urgent need to focus appropriate resources
on optimisation of medication dispensing monitoring systems, especially in vulnerable patient groups; for
example those receiving immunosuppressive drugs (9).
Electronic dispensing records holding information on all dispensed prescriptions in primary care, provide
a unique opportunity to monitor dispensing trends. We aimed: 1) to measure the general impact of
COVID-19 on dispensing patterns; 2) create a national research ready dataset of all primary care
dispensing records for the whole population of Wales and 3) to design and implement a tool for
monitoring and visualisation real-time trends.
Method
Study design and data sources
We conducted a retrospective observational study, accessing national patient-level primary care
dispensing data using the SAIL Databank (10)(11). SAIL holds the Welsh Dispensing DataSet (WDDS),
which records information on all national health service (NHS) prescription items dispensed by primary
care dispensing contractors (community pharmacies, dispensing general practices, general practices that
personally administer prescription medication and dispensing appliance contractors) from 2016,
available on a monthly basis currently to end of September 2020. (12)
The WDDS data is provided to the SAIL Databank by NHS Wales Shared Services Partnership (NWSSP).
The data is captured from prescriptions submitted to NWSSP, on a monthly basis, by all primary care
dispensing contractors to claim remuneration for dispensing in accordance with the provisions of the
National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. The
WDDS dataset is limited to NHS prescriptions containing a 2D matrix barcode i.e. those that are produced
by clinical systems in GP practices in Wales. It therefore covers 94% of prescriptions dispensed and
subsequently submitted for reimbursement. Medications for Welsh residents that are dispensed against
non-barcoded prescriptions or dispensed outside Wales are not included in this dataset. These data are
made available to SAIL on a monthly basis with approximately a 6-week lag to allow for o cial reporting
and quality assurance processes (13).
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Dispensing data from 1st of January 2016 to 31st of December 2019 (counterfactual pre-COVID-19, “C16
cohort”) were compared to data from 1st January 2020 to the 31st of September 2020 (COVID-19 year,
“C20 cohort”). For all people who were alive and resident in Wales with a record in the two purpose-built
residency spine datasets (13), drug dispensing history was retrieved from patient-level linked dispensing
record using anonymized linkage  elds, and the date of dispensing of the drugs.
Dispensed items in WDDS are originally coded in Dictionary of Medicines and Devices (DM + D), which
we mapped at a per code level to their corresponding British National Formulary (BNF) code(s) using an
extract of mappings from National Health Service Business Services Authority (NHS-BSA) services
published on December 2020 (14). Where the BSA mapping is not de ned, NHS Terminology Reference-
Data Update Distribution (known as TRUD) tables were used to map DM + D codes to 7th character BNF
codes (15) (see Supplementary 1 for more details on mapping).
Data were aggregated by month and year, for items in each British National Formulary (BNF) chapter. We
compared dispensing rates between the C16 and C20 cohorts for the three main BNF chapters: I)
Cardiovascular Systems, II) Central Nervous System and III) Immunological Products & Vaccines. We
calculated age-standardised dispensing rates per 100,000 population. Five-year age bands were used
with upper bound of all those aging 90 years or more using the 2013 European Standard Population
(ESP) (16). Dispensing trends were assessed based on total quantity of dispensed items for each BNF
Chap. (17) per year and the number of patients who have had at least one item dispensed, as
documented in their WDDS records.
Statistical analysis
Per person dispensing rates were calculated based on the total number of dispensed items and total
number of patients with a dispensing record on each period. Dispensing rates were calculated for 2020
and the counterfactual period of 2016 to 2019. The difference (D) and relative changes (RC) were
calculated for comparison of monthly trends in dispensing between 2020 records and 2019. All statistical
procedures are performed in R (v3.5) and the codes are available at
https://github.com/SwanseaUniversityMedical/WDDS.
Interactive tool
We developed an interactive tool using R shiny (18) which allows dynamic monitoring of trends in the
current year and enables comparison between the most up to date data with previous years’ patterns. The
dashboard is accessible from https://wdds.ml/.
Results
Cohort curation
3,139,662 patients with a total of 353,516,236 dispensing records entered in the WDDS were linked in two
COVID-19 e-cohorts (13). This comprised 87.7% of Welsh residents between 2016 and 2019 (C16) who
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had at least one dispensing record in WDDS and could be successfully linked. The percentage for those
with residency record at the start of 2020 (C20) was 93.5%. A mapping rate of 99.7% was achieved for
mapping all dispensed records from DM + D to BNF codes for individuals in both the C16 and C20
cohorts who had linked data available for analysis (Fig. 1 & Supplementary 1).
Drug dispensing trends
There was a 5.25% increase in total dispensed items in 2020 compared to the previous year (52,357,639
vs 49,747,141; 95% CI [5.21, 5.29]); while, overall rate of dispensed items per person remained unchanged:
26.25 items were dispensed per individual in 2019 and 25.92 in 2020 representing an Difference (D) of
-0.3 and a Relative Change (RC) of -0.01% (Table 1.a).
Table 1



























2020 52,357,639 2,020,298 25.92 69,810,185 2,057,953 33.92
2019 49,747,141 1,895,365 26.25 66,539,725 1,998,607 33.29
2018 48,798,853 1,940,080 25.15 65,591,106 2,042,733 32.11
2017 46,554,918 1,978,408 23.53 62,522,297 2,090,082 29.91
2016 45,501,194 2,045,059 22.25 60,739,546 2,155,068 28.18
*Presented numbers include estimate counts for 3 remaining months(Oct, Nov and Dec) of 2020
Comparison of monthly patterns of dispensed items between 2020 and 2019 showed an a notable
difference between the total number of dispensed drug items each month, with an average difference of
290,055 and average RC of 5.52%. In the  rst two months of 2020, total number of dispensed items were
6% higher than 2019 (average D = + 318,939, average RC = + 6%). In March 2020, the total number of
dispensed items was 28% higher than 2019 (D = + 1,501,242, RC = + 28.05%). Fewer items were dispensed
in April 2020 than April 2019 (D= -23,767, RC= -0.42%) and a further negative fall was observed in May
2020, where the total number of dispensed items was 5.88% lower than in May 2019 (D= -339,244, RC=
-5.88). A second peak in total number of monthly dispensed items was observed in June of 2020 (D = + 
565,004, RC = + 10.97%). Although the number of dispensed items increased in June, this was followed
by a further reduction of total numbers in subsequent months with an average of 2.69% lower dispensing
in July and August of 2020 compared to the same periods in 2019 (average D= -153,795, average RC=
-2.69). A third peak representing a 9.7% greater number of dispensed items was observed in September
2020 compared to September 2019 (D = + 529,442, RC = + 9.75%) (Table 1.b).
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Overall, comparison of relative changes in dispensing for 2020 vs 2019, between the  rst peak in
dispensing in March (RC = + 28.05%), the second peak in June (RC = + 10.97%) and third peak in
September (RC = + 9.75%) indicates a progressive return towards pre-COVID-19 monthly dispensing
patterns.
The observed increase in in March was consistent for items in the majority of BNF chapters, except for
items in the Anaesthesia and the Immunological products & Vaccines and Dressings chapters, where the
dispensing patterns were different to the overall patterns (Fig. 2. For dynamic comparisons of all years,
please see Supplementary Figs. 2.1 & 2.2 or visit out online dashboard at http://wdds.ml/).
Trends of drug dispensing rates in three selected major BNF
sections over years
Using age standardised dispensing rates, we focused on the comparison between 2019 and 2020 for
Cardiovascular Systems (CVS), Central Nervous Systems (CNS) and Immunological Products and
Vaccines (IPV). All three groups showed similar trends between the years for January and February. For
CVS, dispensing increased considerably during March, however for subsequent months there was
generally reduced dispensing, until recovery to 2019 levels in September (Fig. 3 – Supplementary
Fig. 3.1). For CNS, the March 2020 peak was again observed, however only May appeared to show
signi cant reductions compared to 2019 (Fig. 4 – Supplementary Fig. 3.2). The notable outlier was IPV.
Although the 2020 dispensing patterns for January and February mirrored 2019 level, for all other months
(and across all age groups) there was a large decline (Fig. 5 – Supplementary Fig. 3.3).
Table 1.b: number of dispensed items per month of the year










Jan 6,108,259 5,776,287 331,972 5.75
Feb 5,417,522 5,111,617 305,905 5.98
Mar 6,853,990 5,352,748 1,501,242 28.05
Apr 5,747,006 5,723,239 23,767 0.42
May 5,427,000 5,766,244 -339,244 -5.88
Jun 5,717,634 5,152,630 565,004 10.97
Jul 5,825,965 5,986,661 -160,696 -2.68
Aug 5,299,653 5,446,546 -146,893 -2.7
Sep 5,960,611 5,431,169 529,442 9.75
*Signs indicate direction of change in 2020 compared to 2019
Discussion
Summary of  ndings
This rapid assimilation of national dispensing data in Wales resulted in construction and curation of a
research ready linked dataset. Our data have shown in detail, over all BNF chapters, changes in patterns
of drugs dispensed during COVID-19 period. In general, the peak in total numbers of dispensed items
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coincided with the  rst UK national lockdown, at the  rst peak of the epidemic in March 2020. Our web
application tool was developed for this comparative analysis using aggregated level data to enable
timely monitoring of dispensing trends over time as the care system adapts to the evolving challenges of
the pandemic.
We observed a dramatic reduction in the dispensing of Immunological Products & Vaccines at the start of
lockdown in COVID-19 period. While routinely dispensed vaccines in pharmacies are mainly related to
travel - such as yellow fever and rabies, the demand for these have naturally been reduced during the
COVID-19 period. Similarly, obtaining vaccines from pharmacies through practice nurses prior to house
visits may have been less frequent during COVID-19 lockdown periods. The current COVID-19 pandemic
has perturbed routine immunisation and has led to dramatic shifts in the dispensing of Immunological
Products & Vaccines (19)(20).
While our observation matches to what has been reported in other studies such as Kaye et al. (5); the
increase of dispensed items in March cannot solely be considered as a better adherence. Our data
showed that this peak occurred in most drug categories and was followed by a dip in the following two
months (lockdown period) which is suggestive of batch-dispensing in preparation of the national
lockdowns. It is also likely that patients may have had spare prescriptions to hand and felt an urgent to
get them dispensed.
Strengths and limitations
The patient level data used in our study are available as a monthly extract to SAIL Databank at the
patient level; this provides the opportunity to use aggregated level data for monitoring trends in near real-
time, as well as exploring the effect of patient-level factors such as age, sex, socioeconomic status and
ethnicity. This mechanism provides the powerful opportunity to using these data not only to monitor and
evaluate prescribing and dispensing trends in near real-time, but also to explore the effect of changing
treatment patterns on outcomes considering a comprehensive selection of patient-level factors. Our study
developed a version of the linked dispensing data which was has mapped DM + D codes to the BNF
codes and chapters. This provides an opportunity to further investigate trends within each drug category,
as well as wider collaboration across harmonised data sources.
Conclusion
Dispensing patterns can be used as a proxy measure for monitoring community and population level
effects of COVID-19 on healthcare services. By providing a unique and transparent system for continuous
monitoring of drug prescribing and dispensing, this approach offers an unprecedented opportunity to
evaluate the clinical and health economic impacts of changes in treatment patterns, potentially
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